Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

摘要: We examined the long-term safety and efficacy of zidovudine therapy in 229 subjects with acquired immunodeficiency syndrome (AIDS) AIDS-related complex who previously participated a placebo-controlled study zidovudine. One hundred two placebo recipients (delayed treatment group) 127 (original were followed up while receiving for mean 21 months. Survival rates original group 84.5% 57.6% at 12 months, respectively; delayed group, 78.8% 64.6% respectively, 47.5% 77 AIDS 93.0% 71.8%, 50 group. Adverse reactions decreased over time newly observed toxic unusual. The clinical course these suggests continued survival benefits therapy.